285 related articles for article (PubMed ID: 23885909)
41. Molecular oncology of lung cancer.
Toyooka S; Mitsudomi T; Soh J; Aokage K; Yamane M; Oto T; Kiura K; Miyoshi S
Gen Thorac Cardiovasc Surg; 2011 Aug; 59(8):527-37. PubMed ID: 21850578
[TBL] [Abstract][Full Text] [Related]
42. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
43. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
44.
van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
[TBL] [Abstract][Full Text] [Related]
45. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
[TBL] [Abstract][Full Text] [Related]
46. MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
Reis H; Metzenmacher M; Goetz M; Savvidou N; Darwiche K; Aigner C; Herold T; Eberhardt WE; Skiba C; Hense J; Virchow I; Westerwick D; Bogner S; Ting S; Kasper S; Stuschke M; Nensa F; Herrmann K; Hager T; Schmid KW; Schuler M; Wiesweg M
Clin Lung Cancer; 2018 Jul; 19(4):e441-e463. PubMed ID: 29631966
[TBL] [Abstract][Full Text] [Related]
47. mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma.
Kerr DA; Busarla SVP; Gimbel DC; Sohani AR; Nazarian RM
Hum Pathol; 2017 Jul; 65():157-165. PubMed ID: 28506734
[TBL] [Abstract][Full Text] [Related]
48. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
49. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer.
Subramanian J; Corrales L; Soulieres D; Morgensztern D; Govindan R
J Thorac Oncol; 2011 Feb; 6(2):399-403. PubMed ID: 21206384
[TBL] [Abstract][Full Text] [Related]
50. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
51. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.
Gerber DE; Oxnard GR; Govindan R
Clin Pharmacol Ther; 2015 May; 97(5):447-50. PubMed ID: 25677079
[TBL] [Abstract][Full Text] [Related]
52. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
53. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
54. A systematic review of targeted agents for non-small cell lung cancer.
Vestergaard HH; Christensen MR; Lassen UN
Acta Oncol; 2018 Feb; 57(2):176-186. PubMed ID: 29172833
[TBL] [Abstract][Full Text] [Related]
55. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
Rossi G; Graziano P; Leone A; Migaldi M; Califano R
Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
[TBL] [Abstract][Full Text] [Related]
56. Multigene Panel Testing in Oncology Practice: How Should We Respond?
Kurian AW; Ford JM
JAMA Oncol; 2015 Jun; 1(3):277-8. PubMed ID: 26181167
[No Abstract] [Full Text] [Related]
57. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
58. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
59. Precision and predictive medicine in urothelial cancer: are we making progress?
Bellmunt J; Orsola A; Sonpavde G
Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
[TBL] [Abstract][Full Text] [Related]
60. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
